OBJECTIVES

The objective of this study was to gain insights into the objectives of treatment, patient journey, patient types, factors influencing treatment strategies in multiple myeloma in Sweden and test the need for panobinostat (Farydak®) as a treatment option.

METHODS

The modified Delphi panel was divided into three distinct iterative phases, consisting of individual discussion, group discussion and a clinician consensus and feedback session. All meetings were conducted virtually. Using questionnaires for each phase, the Delphi was thoughtfully prepared to reduce the range of responses, to ultimately achieve consensus. Three Swedish key opinion leaders participated. The questionnaires covered the patient journey and profile, treatment regimens and unmet need in multiple myeloma. Responses from the first phase were then distributed to the physicians, to be discussed in phase 2. The second phase of the process explored place in therapy of the novel drug, Panobinostat (Farydak®).

RESULTS

There are approximately 3,500 myeloma patients in Sweden currently, a number which is increasing due to increased survival. Most patients fall under the ‘relapsed’ category. Age is the most important factor when deciding a treatment. The limitation of most treatments is cost. First line treatment is based on guidelines, whilst patient responses guide choice of later therapy. Oral treatments are the most convenient. While uncommon, home care treatments do happen in some areas. Current treatments are continuous: discontinuation only occurs when the side effects become intolerable. Some patients (approximately 20%), are not administered bortezomib past the first line of treatment due to neuropathy. Clinicians noted that panobinostat (Farydak®), with new clinical data would appear to have a place in treatment for patients in Sweden.

CONCLUSIONS

Panobinostat (Farydak®) could be beneficial for the future management of multiple myeloma. There is a place in therapy for a drug which provides a prolonged patient response, if proven cost-effective.